AZD1152

DRUG8 trials

Sponsors

AstraZeneca, Oxford University Hospitals NHS Trust

Conditions

Acute Myeloid LeukaemiaAcute Myeloid LeukemiaLymphomaMyeloid LeukemiaSolid TumorsSolid Tumours

Phase 1

AZD1152 in Patients With Advanced Solid Malignancies-Study 3

TerminatedNCT00497679

AstraZenecaSolid Tumours

Start: 2006-08-31End: 2007-07-31Target: 45Updated: 2009-05-14

Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia

CompletedNCT00497991

AstraZenecaMyeloid Leukemia

Start: 2006-05-31End: 2010-04-30Updated: 2010-12-08

AZD1152 in Patients With Advanced Solid Malignancies-Study 1

TerminatedNCT00497731

AstraZenecaSolid Tumors

Start: 2005-05-31End: 2009-04-30Target: 70Updated: 2009-06-22

Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

CompletedNCT00530699

AstraZenecaAcute Myeloid Leukaemia

Start: 2007-11-30End: 2009-08-31Target: 30Updated: 2009-09-11

Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC)

CompletedNCT00926731

AstraZenecaAcute Myeloid Leukemia

Start: 2009-06-30End: 2011-05-31Updated: 2011-06-16

An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML)

CompletedNCT01019161

AstraZenecaAcute Myeloid Leukaemia

Start: 2009-11-30End: 2010-06-30Updated: 2010-10-20

AZD1152 in Diffuse Large B-cell Lymphoma

CompletedNCT01354392

Oxford University Hospitals NHS TrustLymphoma

Start: 2011-09-30End: 2013-09-30Updated: 2014-07-02

Phase 2

Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients

CompletedNCT00952588

AstraZenecaAcute Myeloid Leukemia

Start: 2009-07-31End: 2011-06-30Updated: 2020-02-24

Related Papers

A Phase 2 Trial of AZD1152 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Blood2014-12-062 citations

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.

2012-10-15175 citations

Phase 1/2 study to assess the safety, efficacy, and pharmacokinetics of barasertib (AZD1152) in patients with advanced acute myeloid leukemia.

2011-10-05103 citations